Prof Peter Borchmann presents the primary analysis of the pivotal DALY 2-EU trial comparing zamtocabtagene autoleucel with standard of care in non-transplant-eligible patients with relapsed or refractory large B-cell lymphoma (r/r LBCL), meaning disease that has returned after or failed to respond to prior therapy.

He highlights improved event-free and progression-free survival, higher complete response rates, rapid manufacturing timelines, and a manageable safety profile with low rates of severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome (ICANS) in an elderly, high-risk population.